APLT — Applied Therapeutics Share News
0.000.00%
Last trade - 00:00- $15.67m
- $3.73m
- $0.46m
US FDA extends review of Applied Therapeutics' genetic disease drug
U.S. RESEARCH ROUNDUP-Altair Engineering, Applied Therapeutics, Microsoft
Brief: Applied Therapeutics Files Prospectus For Disposition
Brief: Applied Therapeutics FY EPS USD -1.42
Brief: Applied Therapeutics Entered Into Securities Purchase Agreement For Private Placement On Feb 27
Applied Therapeutics gains after FDA grants priority review for rare disease drug
Brief: Applied Therapeutics Announces $100 Million Private Placement
Brief: Applied Therapeutics Announces FDA Acceptance And Priority Review Of New Drug Application For Govorestat For The Treatment Of Classic Galactosemia
U.S. STOCKS ON THE MOVE-Super Micro, Albemarle
U.S. STOCKS ON THE MOVE-Ginkgo, Jfrog, Alvotech
U.S. STOCKS ON THE MOVE-EPAM, CBRE, Zebra Technologies
Applied Therapeutics rises on interim late-stage data for hereditary disease drug
Newscasts - US Markets Briefing: Banks to dominate earnings releases
U.S. STOCKS ON THE MOVE-Greenbrier, Abercrombie & Fitch
U.S. STOCKS ON THE MOVE-CVS Health, Peloton, Eli Lilly
U.S. STOCKS ON THE MOVE-Conagra Brands, Voyager Therapeutics, McDonald's
U.S. STOCKS ON THE MOVE-Apple, Applied Therapeutics, PayPal
Applied Therapeutics falls after heart drug disappoints in late-stage trial
Applied Therapeutics falls after heart drug disappoints in late-stage trial